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Abstract
Purpose. Differentiation of the Mycobacterium tuberculosis complex (MTBc) from non-tuberculous mycobacteria (NTM) is
important for tuberculosis diagnosis and is a prerequisite for reliable phenotypic drug-resistance testing. We evaluated the
performance of the rapid MPT64 antigen identification test for the detection of Mycobacterium africanum lineage 5 (MAF L5).
Methodology. Smear-positive tuberculosis patients’ sputa were included prospectively. Culture was performed on
Löwenstein–Jensen medium and, when positive, the MPT64 test and the classical para-nitro benzoic acid susceptibility and
heat-labile catalase (PNB/catalase) identification tests were performed. The MPT64 test was repeated 14 days after an
initially negative first testing. Direct spoligotyping was performed for MTBc lineage determination.
Results. In total, 333 isolates were tested for all of the methods. Three hundred and twenty-two (96.7%) were pure MTBc, by
agreement between spoligotyping and PNB/catalase, and 11 were NTM or a mixture of MTBc/NTM. The MPT64 test
conducted on day zero of culture-positivity correctly identified most of the pure MTBc isolates (93.2%, 300/322), but it failed
to detect 24% of the L5 isolates (18/75) versus 2% (4/202) of the L4 ones [OR=15.6 (5.3–45.8), P<0.0001], with improved
sensitivity for L5 detection on repeat testing after 14 days. The L5-wide non-synonymous single-nucleotide polymorphism in
the mpt64 gene may explain the poor performance of the MPT64 test for L5.
Conclusion. The MPT64 test has a lower sensitivity for detecting L5 isolates of the MTBc, and can be considered as a first-
screening test that should be confirmed by another identification method when it produces negative results in countries with
L5. Given the microbiological bias in both the isolation and identification of MAF lineages, diagnostics with high sensitivity for
direct testing on clinical material are preferable.
INTRODUCTION
Tuberculosis (TB) remains a public health problem, espe-
cially in low-resource countries, where 95% of global tuber-
culosis is detected [1]. Microscopic detection of acid-fast
bacilli (AFB) has been the main TB diagnostic tool for more
than a century, yet it cannot distinguish MTBc
(Mycobacterium tuberculosis complex) from non-tubercu-
lous mycobacteria (NTM) [2]. The advent of the molecular
Cepheid GeneXpert MTB/RIF test partially resolved this
problem, as it can confirm the presence of MTBc but not
NTM, and is also more sensitive than AFB microscopy for
TB diagnosis [2]. Nevertheless, compared to culture, GeneX-
pert MTB/RIF still has a lower sensitivity for the diagnosis of
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TB in smear-negative pulmonary and extra-pulmonary
specimens [3, 4], as well as for TB in children [4]. Culture
thus remains the most sensitive laboratory test for the diag-
nosis of TB. The isolation of strains in culture is also a prereq-
uisite for conventional phenotypic drug susceptibility testing
(DST) techniques. When a culture is positive, the rapid dif-
ferentiation of MTBc from NTM is necessary for prompt TB
treatment initiation to ensure a better outcome. Moreover,
the differentiation of MTBc from NTM is crucial for a valid
interpretation of resistance patterns in phenotypic DST
assays, as NTM can be intrinsically resistant to anti-TB drugs
and can bemistaken formultidrug-resistantMTBc.
Many techniques have been described for the differentiation
of MTBc from NTM, such as growth in the presence of
para-nitro benzoic acid (PNB), the heat-labile catalase test,
cord-formation ability, hybridization with specific molecu-
lar probes and high-performance liquid chromatography
[5, 6]. Due to their speed and simplicity, the most popular
tests are the rapid and simple immuno-chromatographic
methods, which yield results in 15 min [2]. The MPT64
antigen test was reported to be highly sensitive and specific
for the identification of MTBc in a systematic review [7].
Few studies have included strains isolated from solid
medium [7, 8] or measured the performance of the test for
different MTBc lineages [9].
The human-adapted MTBc members comprise M. tubercu-
losis sensu stricto and Mycobacterium africanum (MAF).
The latter is subdivided into MAF West African 1 and 2,
also called lineages 5 (L5) and 6 (L6), respectively, and is
mostly restricted to the West African region, where it causes
up to 40% of TB [10]. Recently, a study in The Gambia,
where L6 is prevalent, found that the MPT64 antigen test
has low sensitivity for the detection of L6 isolates grown in
automated liquid mycobacterial growth indicator tubes
(MGITs) [9], while the sensitivity of the test for the detec-
tion of L5 isolates remains unknown. Nevertheless, a recent
study found a substitution (I43N) in the mpt64 gene of L5
isolates in Ghana [11], while Gagneux et al. [12] suggested
that L5 has a non-synonymous single-nucleotide polymor-
phism (nSNP; not specified) in the mpt64 gene that could
impact negatively on the performance of the MPT64 anti-
gen test for L5 detection, affecting countries where this line-
age is endemic.
We evaluated the performance of the MPT64 antigen rapid
identification test for L5 detection on isolates from solid cul-
ture medium in Benin, where L5 causes up to one-third of
human TB [13, 14], and compared the available L5 and L6
genomes for nSNPs in the mpt64 gene.
METHODS
Patient selection and specimens
Presumptive TB patients were systematically screened with-
AFB microscopy nationwide through the 24 largest TB clin-
ics in Benin from April to December 2016. TB patients with
smear-positive sputa were prospectively recruited. In each
TB clinic, all retreatment TB patients and a sample of new
TB patients (the next four diagnosed after a retreatment TB
patient) were included. Their sputa were collected before
the initiation of TB treatment and then shipped to the
National Reference Laboratory for Mycobacteria (Labora-
toire de Reference des Mycobacteries) in Cotonou, Benin,
where further laboratory analyses were performed.
Specimen preparation: sputum decontamination
and culture of mycobacteria
The sputa were decontaminated using the Petroff method
[5] (2% NaOH final for 15min and neutralization using
1N HCl containing phenol red), followed by centrifugation
at 3000 g and 4

C for 20min. The pellet was resuspended in
1.5ml of phosphate-buffered saline (PBS). Two standard
Löwenstein–Jensen (LJ) slants and one LJ slant without
glycerol but supplemented with 0.5% sodium pyruvate were
inoculated per patient’s sputum and then incubated at 37

C
and read weekly for 13weeks (90 days) before a negative
culture was reported. An aliquot of the sediment was stored
at  20

C for direct spoligotype analysis.
MPT64 antigen rapid identification test
The SD Bioline TB Ag MPT 64 Rapid assay (Standard Diag-
nostics, Republic of Korea) was used for the identification of
isolates from culture-positive specimens following the man-
ufacturer’s instructions [15]. The test was performed at day
0 (D0) and, if negative, was repeated 14 days later (D14). D0
was defined as the date when primary colonies were large
enough that they could be scraped from the slant. The test
was repeated at D14 on colonies remaining on the primary
slant after it had been reincubated at 37

C. A few colonies
were suspended in 200 µl of the extraction buffer provided
in the kit or in the condensation fluid (if any) of the slant
[15]. Then, 100 µl of this suspension was deposited in the
sample well of the MPT64 device [15]. After 15min incuba-
tion, the MPT64 was reported as negative if a colour signal
line only appeared in the control band and not in the test
band, and as positive if a colour signal line appeared in the
test band as well[15]. For MPT64-positive isolates, the
intensity of the positive colour signal line was also recorded
as ‘strong’ (strong intensity) or ‘faint’ (weaker intensity).
MPT64 devices were double-read by another person who
was blinded for the results of the first reading, mainly
because of faint positivity signals. The MPT64 antigen test
was performed without prior knowledge of the spoligotype
analysis results (spoligotype analysis for all specimens was
performed in batches after the availability of the MPT64
results). The MPT64 test, spoligotype analysis and conven-
tional identification were performed blindly by different
persons.
Conventional identification with PNB/catalase along
with DST
Identification with PNB on LJ medium was performed
along with first-line DST. Mycobacterial suspensions were
inoculated on LJ medium with a final concentration of
500 µgml 1 PNB and on LJ control slants, as described by
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1719
Downloaded from www.microbiologyresearch.org by
IP:  131.152.195.81
On: Thu, 13 Dec 2018 08:31:09
the International Union Against Tuberculosis and Lung
Diseases (IUATLD) [5]. The first-line DST included, as
usual, rifampicin, isoniazid, streptomycin and ethambutol,
respectively, at the critical concentrations of 40 µg ml 1, 0.2
µg ml 1, 4 µg ml 1 and 2 µg ml 1 using the proportion
method on LJ medium [5, 16]. As recommended by the
IUATLD [5], when an isolate was PNB-susceptible and
resistant to at least one of the first-line drugs, it was tested
for the production of 68

C-labile catalase to rule out NTM.
DNA extraction and spoligotyping
For each specimen, 200 µl of decontaminated sputum from
the aliquot that had been stored at  20

C was heat-inacti-
vated at 100

C for 5min [17], followed by DNA extraction
in 300 µl elution buffer using the Promega Maxwell16 Tis-
sue DNA Purification kit (AS1030)[18] with the Promega
Maxwell 16 machine model AS2000 version 4.9, as
described previously [19]. A mycobacterial sediment known
to be PCR-positive for MTBc was included as a positive
extraction control and distilled water was used as a negative
extraction control. Spoligotyping (PCR followed by hybrid-
ization) was then performed as previously described [19,
20]. The M. tuberculosis H37Rv and Mycobacterium bovis
BCG reference strains were included as positive PCR con-
trols and distilled water was used as a negative control. The
MTBc lineage was assigned using the online tool, the TB-
Lineage database [21].
Determination of NTM species and prevalence in
the study population
The Genotype Mycobacterium CM version 1 (Hain Life-
science) [16], molecular species identification test was used
to identify presumed NTM isolates or MTBc/NTM mixtures
based on PNB, catalase and spoligotyping results. DNA was
extracted from the isolates by heat inactivation (100

C for
20min)[17, 19]. PCR followed by hybridization of the PCR
products on the Genotype Hain CM strip were performed
as described by the manufacturer [22]. The H37Rv reference
strain was included as a positive control and distilled water
was used as a negative control. After hybridization, the
strips were fixed on an interpretation sheet and interpreted
following the species profiles provided by the manufacturer.
Single-nucleotide polymorphism (SNP) analysis of
mpt64 gene in L5
To better understand the MPT64 test performance obtained
for the L5 strains in our study, we investigated whether
mutations are present in their mpt64 gene (Rv1980c) using
Snippy 3.1 [23] with H37Rv (NC_000962.3) as the reference
MTBc genome. The available whole-genome sequences
(FastQ files, File S1) from 25 strains belonging to L5 previ-
ously isolated in different countries were used (21 from
Benin, 2 from Ivory Coast and 2 from Guinea). As a control
group, we also checked for the presence of mutations in the
mpt64 gene of the 18 L6 strains (2 from Benin, 4 from
Fig. 1. Specimen flow chart. *, using PNB/catalase and GenoType CM. †, MPT64 could not be repeated at D14 as very few colonies
remained on the LJ slants, which were used for DST and PNB/catalase. ‡, eugonic isolate: isolate with easily scrapable colonies that
grow easily in subculture. §, dysgonic isolate: isolate with very small dry flat or convex [27], hardly scrapable colonies, not improved
by subculture. Dysgonic colonies can be hardly visible.
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Burkina-Faso, 3 from Guinea, 5 from Ivory Coast and 4
from Senegal) for which genomes were available. For
genome sequencing, multiplexed Illumina libraries were
prepared following manufacturer’s guidelines using custom
multiplex tags. Pooled samples were sequenced on an Illu-
mina HiSeq2000 using the V4 kit to produce paired-end
reads that were 100 bp in length. We aimed to attain an
average depth of coverage of ~100-fold for each sample.
Statistical analyses
We used Stata12.0 (StataCorp, USA) for statistical analyses.
The McNemar exact Chi-squared test was used to compare
paired data, and Fisher’s exact test was used for
independent data.
The odds ratios (OR), sensitivity, specificity, positive likeli-
hood ratio (LR+) and negative likelihood ratio (LR ) were
all calculated, along with the 95% confidence interval (CI).
The difference was considered significant when the two-
sided P-value was below 0.05.
RESULTS
Specimens testing flow
The specimen flow chart is presented in Fig. 1.
Overall performance of MPT64 test
MPT64 at D0
In total, 397/434 (91.5%) positive cultures had MPT64
results available (Fig. 1, Table 1). Using either spoligotyping
[19, 20] or PNB/catalase [5] as the reference standard for
MTBc identification, 93.4% (366/392; 95%CI: 90.4–95.6)
and 93.2% (300/322; 95%CI: 89.8–95.7) of MTBc isolates
were correctly classified as MTBc by the MPT64 test,
respectively (Table 1). The PNB/catalase results showed that
six isolates (2 MPT64-positive and 4 MPT64-negative) iden-
tified as MTBc using spoligotyping were identified pheno-
typically as NTM (PNB/catalase), suggesting the presence of
MTBc and NTM in the same specimen. This could be due
to a mixed infection of MTBc/NTM (Table 1). Excluding
these isolates from the analysis, 93.2% (300/322; 95%CI:
89.8–95.7) of MTBc isolates were correctly classified as
MTBc by the MPT64 test on D0, with a specificity of 80%
(4/5; 95%CI:28.4–99.5 (Table 1).
MPT64 at D14
The MPT64 test was repeated at D14 for 19 of the 22 iso-
lates with a negative MPT64 test at D0 (Fig. 1). Seven of the
19 isolates became MPT64-positive, increasing the sensitiv-
ity of the MPT64 test to 96.2% (307/319; 95%CI: 93.5–98),
considering PNB/catalase and spoligotyping agreement as
the reference standard (Table 1).
Table 1. Overall performance of the MPT64 antigen test at day 0 (D0) and at day 14 (D14)
MPT64 Spoligotyping PNB/catalase Combined PNB/catalase + spoligotyping Sensitivity
(95% CI)
Specificity
(95% CI)
LR+ (95% CI)
LR  (95% CI)
MPT64 at D0 MTBc No profile (NTM or test
failure)
Total MTBc NTM Total Pure
MTBc
NTM Mixture
spol MTBc + pnb
NTM
Total Sen: 93.2 (89.8–
95.7)
Spe: 80 (28.4–
99.5)
LR+: 4.7 (0.8–
26.9)
LR : 0.09 (0.05–
0.16)
+ (MTBc) 366 1 367 300 3 303 300 1* 2† 303
  (NTM) 26 4 30 22 8 30 22 4 4‡ 30
Total 392 5 397 322 11 333 322 5 6 333
MPT64 at
D0/D14
MTBc NTM Mixture
spol MTBc + pnb
NTM
Total Sen: 96.2 (93.5–98)
Spe: 80 (28.4–
99.5)
LR+: 4.8 (0.8–
27.8)
LR : 0.05 (0.02–
0.1)
+ (MTBc) 307 1* 2† 310
  (NTM) 12 4 4‡ 20
Total 319§ 5 6 330§
*Identified as MTBc by MPT64 but NTM by PNB/catalase and no spoligo bands or MTBc found using Genotype Mycobacterium CM, which identified
this isolate as Mycobacterium scrofulaceum (or parafunicum or parasrofulaceum).
†MTBc/NTM mixtures confirmed using Genotype Mycobacterium CM on the isolates.
‡Identified as NTM by MPT64 and PNB/catalase (agreement). Spoligotyping of specimens detected the presence of MTBc (two L6, one L4 and one
M. bovis), yet no mixture (MTBc/NTM) found using Genotype CM on the isolates.
§Three isolates that were MPT64-negative at D0 did not have MPT64 repeated at D14 and so are not included in the table.
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Species of NTM identified
Of the 11 isolates phenotypically identified as not being
pure MTBc, 6 were considered to be mixtures (MTBc/
NTM) based on the double banding profile on the Genotype
Mycobacterium CM strip and/or a spoligotyping profile
from the sputum specimen combined with growth of the
isolate on the PNB tube. The five pure NTM isolates
included one M. kansasii, one M. abscessus (or M. immuno-
genum), one M. malmoense (or M. haemophilum, M. pal-
ustre or M. nebraskense), one M. scrofulaceum (or M.
paraffunicum or M. parascrofulaceum) and one M. species.
Among the MTBc/NTM mixtures, two isolates were posi-
tive in the MPT64 assay (Table 1). They were confirmed as
mixtures by Genotype CM and the spoligotype banding
profiles, revealing L4 + M. fortuitum and L6 + M. species.
For the four remaining presumed mixtures, spoligotyping of
the sputum suggested the co-existence of MTBc, whereas no
MTBc was detected in the isolates with only the NTM probe
of the Genotype CM reacting and growth on PNB. The
combined results suggested the following mixtures: M. bovis
+ M. intracellulare, L4 + M. fortuitum and 2 L6 +
M. intracellulare. The overall proportion of NTM identified
was 3.3% (11/333). M. intracellulare followed by M. fortui-
tum were the most observed.
Performance of MPT64 test across MTBc lineages
For the following comparisons, NTMs and mixtures were
excluded; only pure MTBc (PNB/catalase and spoligotyp-
ing-confirmed) isolates (322/333, Table 1) were included.
MPT64 at D0 in MTBc isolates
At D0, MPT64 positivity varied significantly across lineages
(P<0.001, Table 2). MPT64 was positive for all isolates from
lineages 1, 2, 3, 6 and M. bovis, whereas almost one-quarter
(24%) of the MAF L5 isolates and 2% of the L4 isolates
were MPT64-negative. MPT64-positive isolates were signifi-
cantly under-represented among L5 versus L4 isolates, the
most prevalent lineage (OR=0.06, 95%CI: 0.02–0.19,
P<0.0001; Table 2), corresponding to 15.6-fold odds
(95%CI: 5.3–45.8) of MPT64 false-negativity in L5 isolates
(P<0.0001).
MPT64 at D14 in MTBc isolates
The 19 isolates that were MPT64-negative at D0 and repeat
tested at D14 included 16 L5 and 3 L4 isolates. MPT64
became positive for an additional seven (43.8%) L5 isolates,
significantly increasing the positivity of MPT64 from 76%
at D0 to 87.7% at D14 (RR=1.1, 95%CI: 1.0–1.2, P=0.016,
exact McNemar). None of the three L4 isolates that were
MPT64-negative at D0 became positive. Despite the positiv-
ity at D14 of some previously MPT64-negative isolates,
Table 2. Performance of the MPT64 test across MTBc lineages
Only pure MTBc isolates (detected using PNB/catalase and spoligotyping) are included in this comparison
PNB/catalase (All MTBc)
MTBc
lineages
MPT64 at D0 OR with 95% CI, P*
Positive
(MTBc)
Negative Total
L1 15 (100%) 0 15 –
L2 14 (100%) 0 14 –
L3 3 (100%) 0 3 –
L4 198 (98%) 4 202 . OR=0.06 (0.02 to 0.19)
L5 57 (76%) 18 75 . P<0.0001
L6 8 (100%) 0 8 –
M. bovis 5 (100%) 0 5 –
Total 300 22 322 Overall P<0.001
MPT64 at D0-14
L1 15 (100%) 0 15 –
L2 14 (100%) 0 14 –
L3 3 (100%) 0 3 –
L4 198 (98.5%) 3† 201 . OR=0.11 (0.03 to 0.38)
L5 64 (87.7%) 9‡ 73 . P=0.0005
L6 8 (100%) 0 8 –
M. bovis 5 (100%) 0 5 –
Total 307 12 319 Overall P=0.018
*P-values were calculated using Fisher’s exact test.
†MPT64 was not performed at D14 for one specimen that was MPT64-negative at D0 and so it was excluded.
‡MPT64 was not performed at D14 for two specimens that were MPT64-negative at D0 and so they were excluded; MPT64 became positive for seven
specimens.
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MPT64 positivity still varied across lineages (Table 2). The
difference in MPT64 false-negativity between L5 versus L4
isolates was still strongly significant, with 12.3% (9/73) of
L5 isolates versus 1.5% (3/201) from L4 remaining negative
at D14 (false-negativity OR=9.3, 95%CI: 2.6–32.6,
P=0.0005).
Variation of the intensity of the positivity signal (colour)
line of the MPT64 cartridge
At D0, a total of 19 (6.3%) of the 300 MPT64-positive iso-
lates had a faint signal. Most of them were from L5 (24.6%,
14/57), followed by L6 (12.5 %, 1/8), versus only 1.5% (3/
198) from L4 (Table 3). The odds of obtaining a faint signal
in L5 isolates was 21.2-fold (95%CI: 6.2–71.5) the odds of
that for L4 isolates (P<0.0001), which did not decrease after
the D14 repeat (OR=21.7, 95%CI: 6.5–72.2, P<0.0001)
(Table 3). The proportion of isolates with a faint signal was
also higher in the MAF group (L5+L6) versus the non-MAF
group (P<0.0001) or the ancestral lineages group (L1+L5
+L6) compared to the modern lineages group (P<0.0001,
Table 3).
Variation of the time from inoculation (start of
incubation) to the realization of the MPT64 test (Dt).
The median Dt at D0 was shortest for L1, L3 and L4
(3weeks) followed by L2 and M. bovis (4 weeks), L5
(6 weeks) and L6 (8 weeks). Including repeated testing, the
median Dt increased to 8weeks for L5, while it remained
similar for the other lineages (Table S2).
SNP analysis of mpt64 gene in L5
All 25 of the L5 isolate genomes shared the same nSNP
128T>A (I43N) in the mpt64 gene (File S1). One of the L5
genomes had in addition, a synonymous SNP 519G>A
(V197V). Among the L6 isolate genomes, there was no
mutation in the mpt64 gene for 17 of the 18 isolates ana-
lysed. One genome harboured a synonymous SNP 81C>T
(T27T) in the gene.
Lineage distribution among population of isolates
included versus excluded in the MPT64 comparison
The lineage distribution in the isolates (pure MTBc)
included in the MPT64 vs combined spoligotyping and
PNB/catalase comparison differed significantly to the
Table 3. Variation of the intensity of the positivity signal line of the MPT64 strip across MTBc lineages
Intensity of MPT64 cartridge positivity signal band (MPT64 positive specimens)
MTBc Lineages
MPT64 positive at D0 OR (95% CI), P*
Strong signal Faint signal Total
L1 14 1 (6.7%) 15 -
L2 14 0 14 -
L3 3 0 3 -
L4 195 3 (1.5%) 198 .OR=21.2 (6.2–71.5)
L5 43 14 (24.6%) 57 .P<0.0001
L6 7 1 (12.5%) 8 -
M. bovis 5 0 5 -
Total 281 19 300
Modern MTBc (L2+L3+L4) 212 3 (1.4%) 215 .OR=17.7 (5.3–58.4)
Ancestral MTBc (L1 +L5+L6) 64 16 (20%) 80 .P<0.0001
Other than MAF (L1+L2+L3+L4) 226 4 (1.7%) 230 .OR=16.9 (5.6–50.6)
MAF (L5+L6) 50 15 (23.1%) 55 .P<0.0001
MPT64 positive at D0-14
L1 14 1 (6.7%) 15 -
L2 14 0 14 -
L3 3 0 3 -
L4 195 3 (1.5%) 198 .OR=21.7 (6.4–72.2)
L5 48 16 (25%) 64 .P<0.0001
L6 7 1 (12.5%) 8 -
M. bovis 5 0 5 -
Total 286 21 307
Modern MTBc (L2+L3+L4) 212 3 (1.4%) 215 .OR=18.4 (5.6–60.3)
Ancestral MTBc (L1 +L5+L6) 69 18 (20.7%) 87 .P<0.0001
Other than MAF (L1+L2+L3+L4) 226 4 (1.7%) 230 .OR=17.5 (5.9–51.4)
MAF (L5+L6) 55 17 (23.6%) 72 .P<0.0001
*P-values were calculated using Fisher’s exact test.
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distribution in isolates excluded for the unavailability of
MPT64 and/or PNB/catalase results (poor quality for subse-
quent tests) (Table 4). MAF L5 and L6 were significantly
over-represented in that excluded group relative to the
included group (OR=4.5, 95% CI: 2.7–7.5, P<0.0001). The
excluded group of isolates (n=80) included 72 dysgonic and
8 partially contaminated isolates. When comparing the
included group solely to the dysgonic isolates among
the excluded group, we found that the dysgonic nature of
the isolates was strongly associated with the lineage, with L5
and L6 being over-represented among dysgonic isolates
(OR=5.7, 95%CI: 3.3–9.9, P<0.0001), especially L6
(OR=9.5, 95%CI: 3.9–23.1, P<0.0001) (Table 4).
DISCUSSION
Our evaluation of LJ-based primary cultures from smear-
positive TB patients in Benin in a nationwide prospective
study suggests that the SD Bioline MPT64 antigen test offers
relatively low performance for the rapid identification of the
L5 of MTBc. Its lower sensitivity for the confirmation of L5
as MTBc leads to the misclassification of L5 as NTM.
Repeating the test 14 days after a first negative result
improved the sensitivity for L5 detection significantly, but
not completely. The few L4 isolates that tested negative at
D0 (1.5%) remained negative at D14 testing, which could
mean that those L4 isolates and the L5 isolates that were
MPT64-negative at D14 need an incubation time beyond
14 days after D0, or could point to mutations in the mpt64
gene, as found in L4 (including a 63 bp deletion [24]) in
other studies [24, 25]. The MPT64 test positivity at D0 for
L5 isolates cultured on LJ (solid) medium in our study
(76%) was similar to that for L6 isolates cultured in MGIT
(liquid) medium (78.4 %) at the same D0 testing time-point
in the study by Ofori-Anyinam et al., while there was a simi-
lar increase in positivity to that found for L5 at D14 in our
study (87.7%) for L6 at D15 (90.2 %)[9]. In our study, how-
ever, all L6 isolates (n=8) were positive in the MPT64 test,
even at D0. This observed difference – albeit for a small
number – may be explained by the lower performance of
MPT64 for L6 cultured in MGIT than for isolates cultured
on LJ, as mycobacterial growth is more rapid in MGIT (liq-
uid) than on LJ (solid) medium, allowing the production of
a higher quantity of MPT64 protein on LJ compared to in
MGIT. Indeed, a shorter incubation time posed an indepen-
dent risk for a false-negative MPT64 test in the MGIT-based
study [9].
SNP analysis of the mpt64 gene in L5 genomes confirmed
that L5 isolates harbour an nSNP in this gene [11] (also
confirmed in all the 367 L5 genomes available in another
genome collection from various countries; M. Coscolla, per-
sonal communication), leading to a modification of the
amino acid chain of the MPT64 produced by L5 (I43N),
probably impacting on the protein structure. Jiang et al.
[24] found that nSNPs in the mpt64 gene rarely changed the
structure and function of the protein, in contrast to a 63 bp
deletion (amino acids 66–86) that is mostly observed in L4,
but also in some L1 isolates [24–26].
Oettinger et al. created five monoclonal antibodies
(C24b1-3, L24b4-5) that reacted with four epitopes of the
MPT64 antigen [26]. The MPT64 antigen’s epitope for the
C24b3 antibody consists of two structural domains found
in the sequences Ala1-Leu43 and Ala108-Ser152 [26]. The
Ile43Asn mutation (I43N) found in all L5 isolates genomes
coincides with the final amino- acid of the first part of
this epitope. This could lead to partial binding and lower
adherence or prevent the binding of the C24b3 antibody
to its partially modified epitope in the MPT64 antigen,
resulting in a faint positivity signal band or negative
MPT64 test if that antibody was used in the development
of the MPT64 test. The mouse antibodies (at least three)
[15] used in the development of the MPT64 test are not
specified, but are likely included among the five detected
by Oettinger et al. [26], as this paper is cited in the SD
Bioline MPT64 sheet [15]. This could explain why, despite
the non-synonymous mutation in the mpt64 gene of L5,
there was a significant proportion of isolates with faint
positivity signal bands and isolates with strong positivity
signal bands, and a significant proportion of MPT64-nega-
tive isolates (even after a D14 repeat). Nevertheless, chang-
ing the mouse antibody from which the corresponding
MPT64 epitope is mutated in L5 isolates may improve the
sensitivity for L5. It was reported that the MPT64 test has
lower sensitivity for L6 strains [9], although no missense
mpt64 mutations were identified in L6 genomes. So
another mechanism may account for the lower sensitivity
in MAF L5 like for example in MAF L6 strains, in which
the expression of the mpt64 gene was lower than in
M. tuberculosis sensu stricto [9]. More extended gene
expression and regulation studies should be conducted in
order to confirm these possible causes for the lower per-
formance of MPT64 tests for the L5 and L6 MAF lineages.
Importantly, in West Africa where MAF is common,
MPT64-negative tests should be confirmed by another iden-
tification method (such as Genotype Hain CM, IS6110 PCR,
spoligotyping, Cepheid GeneXpert, PNB/catalase) before
being classified as NTM. If available, molecular analyses
[Genotype Mycobacterium CM, IS6110-PCR, spoligotyping,
GeneXpert MTB/RIF (on a diluted bacterial suspension)]
should be prioritized for this confirmation, as these are
more rapid and sensitive (they can identify MTBc in mix-
tures of MTBc/NTM isolates) than PNB/catalase. If only
PNB/catalase is available, further MPT64 testing can be
done at at least day 14 after the first testing (while PNB/cat-
alase is underway) as the result (if positive) can be obtained
more rapidly than that for PNB/catalase.
In our study, MAF isolates were more likely to be dysgonic,
as previously reported [27, 28], particularly for L6. Gehre
et al. found that L6 has non-synonymous mutations in
genes related to growth in culture (aceE, recA, Rv2112 and
Rv0862) that may explain its attenuated growth in culture
[28]. A previous study also indicated that L5 is less likely to
grow in culture compared to M. tuberculosis sensu stricto
[19]. Our findings suggest that, in addition to the lower
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ability of MAF strains to yield a positive culture, the MAF
isolates that are successfully grown are more likely to be
dysgonic, jeopardizing phenotypic post-culture tests. These
findings highlight the need for simple phenotypic or geno-
typic diagnostic tests that can be applied directly to patient
sputa/uncultured specimens to detect all species of the
MTBc, distinguish MTBc strains from NTM, and detect
possible mixed MTBc/NTM infections and drug resistance
against multiple antibiotics.
One strength of our study is that it was conducted in a set-
ting where L5 is common, allowing the prospective assess-
ment of the performance of the MPT64 test for identifying
this lineage as an MTBc member. Testing on primary isola-
tion reflects how the MPT64 test is used in routine practice,
typically on cultures from smear-negative or GeneXpert
MTB/Rif-negative specimens, or extra-pulmonary speci-
mens, and for rapid screening identification before pheno-
typic DST. Our testing was essentially blinded to the strain
lineage, which was determined later and by different techni-
cians. Possible limitations of our study include the fact that
we only used one of the four commercially available MPT64
assays (Capillia, SD Bioline, MGIT TBc and TB Check),
although a study on L6 did not find a difference between
the MPT64 tests provided by different manufacturers [9].
We expect that our findings will therefore be generalizable
to other settings, especially in West and Central Africa,
where L5 is prevalent.
We therefore strongly recommend that the differences in
MTBc lineage characteristics should be considered in diag-
nostics development, so tests will perform equally well in
ancestral lineages such as L5 and L6. Furthermore, their
performance should be evaluated in different settings,
especially where such ancestral lineages are common.
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